Pricing Log in Create free account

Aurinia Pharmaceuticals Inc (AUPH) vs SELLAS Life Sciences Group, Inc. (SLS)

Aurinia Pharmaceuticals Inc and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and SELLAS Life Sciences Group, Inc. are of similar size ($2.3B and $2.2B). SELLAS Life Sciences Group, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Aurinia Pharmaceuticals Inc has the higher net margin (100.8% vs 0.00%) and the higher return on invested capital (40.8% vs 0.00%). Across the 16 metrics below, Aurinia Pharmaceuticals Inc leads on 14 and SELLAS Life Sciences Group, Inc. on 2.

Valuation

Metric AUPH SLS Biotechnology median
P/E 6.91 n/m 8.50
P/S 6.89 179.81 9.71
P/B 3.49 13.72 2.13
Price to free cash flow 12.27 n/m 20.82
EV/EBITDA 10.93 n/m 0.64
EV/Sales 5.61 166.67 9.21
Earnings yield 14.48% (2.10%) (33.15%)
Free cash flow yield 8.15% (2.04%) (25.50%)

Profitability

Metric AUPH SLS Biotechnology median
Gross margin 90.36% 0.00% 65.16%
Operating margin 45.15% 0.00% 0.00%
Net margin 100.84% 0.00% 0.00%
Free cash flow margin 56.20% 0.00% 0.00%
Return on equity 66.12% (39.63%) (56.36%)
Return on assets 48.52% (36.54%) (48.04%)
Return on invested capital 40.76% 0.00% 0.00%

Growth

Metric AUPH SLS Biotechnology median
Revenue growth (TTM) 19.76% — 6.02%
EPS growth (last fiscal year) 5,075.00% 50.00% 30.26%
Revenue growth, 5-year CAGR 41.38% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AUPH SLS Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 5.42 18.83 4.72
Net debt to EBITDA (2.58) 2.54 0.96

Dividend

Metric AUPH SLS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AUPH SLS Biotechnology median
Market cap 2.23b 2.29b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack